

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number  
**WO 02/08205 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 239/34**,  
239/38, 239/42, 239/48, 239/46, A61K 31/505, A61P  
25/00, 25/28, 3/10

(21) International Application Number: PCT/US01/23088

(22) International Filing Date: 20 July 2001 (20.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/220,348 24 July 2000 (24.07.2000) US

(71) Applicant (for all designated States except US): **KRENIT-  
SKY PHARMACEUTICALS, INC.** [US/US]; 4611 Uni-  
versity Drive, Durham, NC 27707 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BEAUCHAMP**,  
Lilia [US/US]; 3003 Wycliff Road, Raleigh, NC 27607  
(US). **KRENITSKY, Thomas, A.** [US/US]; 106 Laural  
Hill Road, Chapel Hill, NC 27514 (US). **KELLEY**,  
**James, L.** [US/US]; 10928 Raven Rock Drive, Raleigh,  
NC 27614 (US).

(74) Agents: **HUMPHREY, Christopher, M.** et al.; Alston &  
Bird LLP, Bank of America Plaza, Suite 4000, 101 South  
Tryon Street, Charlotte, NC 28280-4000 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY

(57) Abstract: The present invention relates to a series of novel substituted 5-alkynyl pyrimidines, pharmaceutical compositions which contain them, methods for their preparation, and their use in therapy, particularly in the treatment of neurodegenerative or other neurological disorders of the central and peripheral nervous systems, including age related cognitive disorders such as senility and Alzheimer's disease, nerve injuries, peripheral neuropathies, and seizure disorders such as epilepsy.



WO 02/08205 A1

SUBSTITUTED 5-ALKYNYL PYRIMIDINES  
HAVING NEUROTROPHIC ACTIVITY

BACKGROUND OF THE INVENTION

The present invention relates to a series of novel substituted 5-alkynyl pyrimidines, to pharmaceutical compositions which contain them, to methods for their preparation and to their use in therapy, particularly in the treatment of neurodegenerative or other neurological disorders of the central and  
5 peripheral nervous systems including age related cognitive disorders such as senility and Alzheimer's disease, nerve injuries, peripheral neuropathies, and seizure disorders such as epilepsy.

Dementing disorders such as age-related cognitive disorders, e.g., senility or  
10 Alzheimer's disease are medical conditions for which there are currently only limited therapies. Although studies suggest that multiple neurotransmitter systems are involved in senile dementia, a loss of cholinergic neurons and a severe depletion of choline acetyltransferase appear to show the earliest and strongest correlation with functional cognitive impairment [see P.T. Francis et  
15 al., Neurochemical Studies of Early-onset Alzheimer's Disease. N. Engl. J. Med., 313, 7 (1985); R.T. Bartus et al., The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions. Ann. N. Y. Acad. Sci., 444, 332 (1985); F. Hefti and L.S. Schneider, Nerve Growth Factor and Alzheimer's Disease, Clin. Neuropharmacol., 14, S62 (1991)].  
20 Several groups have attempted to stimulate cholinergic activity by blocking the breakdown of acetylcholine with acetylcholine esterase inhibitors or by introducing muscarinic or nicotinic agonists [see R.T. Bartus et al., The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science, 217, 408 (1982); J. Varghese et al., Chapter 21. Alzheimer's Disease: Current  
25 Therapeutic Approaches. Annu. Rep. Med. Chem., 28, 197 (1993)]. The

approved drugs COGNEX and ARICEPT are acetylcholine esterase inhibitors.

Nerve growth factor (NGF) is the best characterized neurotrophic factor that is  
5 capable of inducing cell differentiation of neural cells and promoting neurite  
sprouting. The neurotrophic protein NGF primarily affects cholinergic neurons  
in the central nervous system and may be necessary for their survival [see F.  
Hefti and P.A. Lapchak, Pharmacology of Nerve Growth Factor in the Brain.  
Adv. Pharmacol., 24, 239 (1993)]. NGF is not systemically bioavailable, but if  
10 it is injected or infused directly into brain, it prevents neuronal cell loss and  
restores cognitive function in aged or lesioned rats or monkeys [see W.  
Fischer et al., NGF Improves Spatial Memory in Aged Rodents as a Function  
of Age. J. Neurosci., 11, 1889 (1991)]. NGF effects ultimately result in the  
stimulation of choline acetyltransferase, the enzyme for biosynthesis of  
15 acetylcholine and the promotion of neurite growth. Consequently, small  
molecules that produce neurotrophic or "nerve growth factor-like" (NGF-like)  
properties in mammalian cell cultures have potential for use in the treatment  
of dementing disorders such as age-related senility or Alzheimer's disease  
and other neurodegenerative conditions such as peripheral neuropathies,  
20 Parkinson's, stroke damage, transient ischemic attacks, trauma-head injuries  
or other nerve injuries.

Since pancreatic cells producing insulin synthesize, secrete and are  
stimulated by nerve growth factor, another potential use of the compounds of  
25 the present invention is in the treatment of diabetes. [See T. Rosenbaum et  
al., Pancreatic B Cells Synthesize and Secrete Nerve Growth Factor, Proc.  
Natl. Acad. Sci. USA, 95, 7784 (1998)].

There are several reports of small molecules that exhibit various aspects of  
30 NGF-like activity. Isaxonine [2-(isopropylamino)pyrimidine] was developed as  
a neurotrophic pharmaceutical but the clinical application was withdrawn,

possibly due to toxicological effects [see S. Lehmann et al., Neurite Outgrowth of Neurons of Rat Dorsal Root Ganglia Induced by New Neurotrophic Substances with Guanidine Group. *Neurosci. Lett.*, 152, 57 (1993)]. Several 2-(piperazino)pyrimidine derivatives were reported to

5 possess NGF-like activity and are being studied further for use in treating CNS degenerative diseases [see A. Awaya et al., Neurotrophic Pyrimidine Heterocyclic Compounds. *Biol. Pharm. Bull.*, 16, 248 (1993)]. AIT-082 (4[[3-(1,6-dihydro-6-oxo-9-purin-9-yl)-1-oxopropyl]amino]benzoic acid) is reported to enhance NGF action in cultured PC-12 cells and to restore age-induced

10 working memory deficits in mice [see P.J. Middlemiss et. al., AIT-082, A Unique Purine Derivative, Enhances Nerve Growth Factor Mediated Neurite Outgrowth from PC-12 cells. *Neuroscience Let.*, 199, 131 (1995)]. The compound SR57746A is reported to have nerve growth factor potentiating activity and is in clinical trials [see Fournier J, et al. Protective Effects of

15 SR57746A in Central and Peripheral Models of Neurodegenerative Disorders in Rodents and Primates. *Neuroscience*, 55(3), 629-41, Aug 1993; US Patents 5,270,320 and 5,462,945]. The compound BW 394U, 2-amino-5-(4-chlorophenyl)thio-4-morpholinopyrimidine, is described as a potential antisenility agent [see Samano et. al., *J. Heterocyclic Chem.*, 37, 183 (2000)].

20 In addition, WO98/12190, WO99/19305, WO00/59893, WO00/61562, EP0372934, EP0459819 and U.S. Patent 5,075,305 disclose substituted pyrimidines having NGF-like activity and their possible use in treating CNS degenerative diseases like Alzheimer's disease as well as peripheral neuropathies and other disorders of the central and peripheral nervous

25 system. WO94/14780 discloses certain structurally similar pyrimidine derivatives as neuronal nitric oxide synthase inhibitors.


## SUMMARY OF THE INVENTION

30 We have now discovered a novel series of substituted 5-alkynyl pyrimidines that demonstrate NGF-like activity and/or enhancement of NGF activity in

PC12 cells. The compounds stimulated both neurite outgrowth and choline acetyltransferase activity in *in vitro* experiments. Such activities are predictive for causing increased choline acetyltransferase activity in rat striatum and improving cognitive performance in animal models of age-induced working memory deficits by potentiating the activity of endogenous NGF in the brain. [see P.J.. Middlemiss, A.J. Glasky, M.P. Rathbone, E. Werstuik, S. Hindley and J. Gysbers, AIT-082, A Unique Purine Derivative, Enhances Nerve Growth Factor Mediated Neurite Outgrowth from PC-12 cells. Neuroscience Let., 199, 131 (1995); A.J. Glasky, C.L. Melchior, B. Pirzadeh, N. Heydari and R.F. Ritzmannn, Effect of AIT-082, a Purine Analog, on Working Memory in Normal and Aged Mice. Pharmacol. Biochem. Behav., 47, 325 (1994); R. Morris, Developments of a Water-maze Procedure for Studying Spatial Learning in the Rat. J. Neurosci. Methods, 11, 47 (1984)].

## DETAILED DESCRIPTION OF THE INVENTION

According to the present invention, there are provided novel compounds of Formula I:



Formula I

wherein

Z is O, NH or S, and m is 0 or 1;

R<sub>1</sub> is (C<sub>2</sub>-6alkyl)<sub>a</sub> (C<sub>3</sub>-10cycloalkyl, C<sub>2</sub>-9heterocycloalkyl, C<sub>5</sub>-

10aryl, or C4-9heteroaryl)<sub>b</sub>(C1-6alkyl)<sub>c</sub>, wherein a, b and c are independently 0 or 1, provided that at least one of a, b and c is 1 and if b is 0, then c is also 0, and wherein the heterogroups include an N, O or S atom and the C and N atoms of R<sub>1</sub> may optionally be substituted with one or more substituents selected from the group consisting of:

OH;

halogen:

thio;

oxo;

thioxo;

carboxy;

carboxamide;

C1-7alkylcarbonyl;

C1-7alkylcarbonyloxy

C1-7alkylthiocarbonyl;

C1-8alkyloxy;

hydroxyC2-8alkyloxy;

di-C1-8alkylphosphate ester

C1-8alkylthio;

hydroxyC2-8alkylthio;

C1-8alkylsulfinyl;

C1-8alkylsulfonyl;

C1-5alkyloxyC1-5alkyl;

C1-5alkylthioC1-5alkyl;

C1-5alkylsulfinylC1-5alkyl; and

C1-5alkylsulfonylC1-5alkyl;

R<sub>2</sub> is selected from the group consisting of H, NH<sub>2</sub> and NH-CO-R<sub>3</sub>, where R<sub>3</sub> is H or C1-12 alkyl;

X is C6-10aryl optionally substituted with one or more substituents (y) selected from the group consisting of:

- OH;  
NO<sub>2</sub>  
5 NH<sub>2</sub>  
NH-CO-R<sub>4</sub> where R<sub>4</sub> is H, C1-12alkyl, aryl or (C1-6alkyl)aryl  
halogen;  
C1-6alkyl;  
hydroxyC1-6alkyl;  
10 oxoC2-7alkyl;  
C2-7alkenyl;  
C2-7alkynyl;  
C1-6alkoxy;  
CF<sub>3</sub>;  
15 CF<sub>3</sub>C1-6alkyl;  
OCF<sub>3</sub>; and  
CF<sub>3</sub>C1-6alkoxy;  
and pharmaceutically acceptable esters, amides, salts or solvates thereof.
- 20 By "alkyl" is meant straight or branched chain alkyl. By "heterocycloalkyl" is meant a saturated ring containing 1 to 4 heteroatoms selected from the group consisting of N, O and S. By "aryl" is meant an aromatic ring such as phenyl or naphthyl. By "heteroaryl" is meant an aromatic ring containing 1 to 4 heteroatoms selected from the group consisting of N, O and S. By "halogen"
- 25 is meant F, Cl, Br or I.

The present invention includes all enantiomeric and diastereomeric forms of the compounds of Formula I either individually or admixed in any proportion.

- 30 The present invention further includes prodrugs and active metabolites of the compounds of Formula I. A prodrug includes any compound which, when

administered to a mammal, is converted in whole or in part to a compound of Formula I. As is well known in the pharmaceutical arts, a specific drug compound may be utilized in its active form, or in the form of a "prodrug" which is converted to the active form (or to an active metabolite) of the compound when administered to the patient. In the present invention, esters or amides of the compounds of Formula I which are hydrolyzed in the body to form the compounds of Formula I are examples of prodrugs of such compounds. An active metabolite is a physiologically active compound which results from the metabolism of a compound of Formula I, or a prodrug thereof, when such compound or prodrug is administered to a mammal. It is well known that drugs are metabolized by the body into a variety of derivative compounds, one or more of which may be responsible in whole or in part for the recognized activity of the drug. Such metabolites of the drug constitute an inherent part of the underlying drugs of the present invention, but must be identified individually for each compound by blood analysis of the patient. Such identification is well within the skill of the art and is routinely practiced as a part of the clinical evaluation and regulatory approval process for commercial drug products. Accordingly, while specific metabolites cannot be identified herein for all the compounds encompassed by the present invention, the identification of metabolites for any given compound is merely a routine undertaking once that compound has been selected for administration to a mammal. Prodrugs and active metabolites of the compounds of the present invention, therefore, are an inherent part of the invention and intended to be included within the scope thereof.


25

Preferred compounds of Formula I are those wherein X is phenyl which is unsubstituted or substituted at the 4-position. Particularly preferred are those compounds wherein X is phenyl substituted with 4-chloro, 2,4 dichloro, 4-bromo, 2-fluoro-4-chloro, 2-chloro-4-fluoro, 2-methyl-4-chloro, 4-methyl, 4-ethyl or 4-acetamido. Also preferred are those compounds wherein R<sub>1</sub> is an oxy or hydroxy substituted phenyl, phenylethyl, cyclohexyl, alkyl or

30



- alkoxyalkyl. Particularly preferred are those compounds where  $(Z)_m-R_1$  is 4-oxocyclohexylamino, trans-4-hydroxy-cyclohexylamino, cis-4-hydroxycyclohexylamino, 4-hydroxyanilino, 4-methoxyanilino, 3,4-dimethoxyanilino, 4-hydroxypiperdino, 2-hydroxyethylamino or 2-(2-hydroxyethoxy)ethyl-amino. Yet further preferred compounds of Formula I are those where  $R_2$  is  $NH_2$  or formamido. The compounds of Formula I above and their pharmaceutically acceptable salts or solvates are sometimes hereinafter referred to as "compounds of the present invention".
- 10 Preferred compounds of Formula I are more particularly defined according to the following Formulas IA - IC:




15

Formula IA


wherein p is 0,1 or 2, and each y (which may be the same or different),  $R_1$  and  $R_2$  are as hereinbefore defined;

20



Formula IB

5            wherein p is 0,1 or 2, and each y (which may be the same or different),  
 $R_1$  and  $R_2$  are as hereinbefore defined;



Formula IC

10

          wherein p is 0,1 or 2, and each y (which may be the same or different),  
 $R_1$  and  $R_2$  are as hereinbefore defined.

15    Representative compounds of the present invention are:

2-Amino-5-(4-chlorophenylethynyl)-4-(4-acetylpiperazino)pyrimidine

4-(trans-4-Hydroxycyclohexylamino)-5-phenylethynylpyrimidine

4-[2-(2-Hydroxyethoxy)ethylamino]-5-phenylethynylpyrimidine

20    5-(4-Chlorophenylethynyl)-4-[2-(2-hydroxyethoxy)ethylamino]pyrimidine

2-Amino-5-(4-chlorophenylethynyl)-4-[2-(2-

- hydroxyethoxy)ethylamino]pyrimidine
- 4-[4-(2-Hydroxyethyl)piperazino]-5-phenylethynylpyrimidine
- 2-Amino-4-[4-(2-hydroxyethyl)piperazino]-5-phenylethynylpyrimidine
- 2-Amino-5-(4-chlorophenylethynyl)-4-[4-(2-hydroxyethyl)piperazino]pyrimidine
- 5 4-(4-Hydroxypiperidino)-5-phenylethynylpyrimidine
- 5-(4-Chlorophenylethynyl)-4-(4-hydroxypiperidino)pyrimidine
- 2-Amino-4-(4-hydroxypiperidino)-5-phenylethynylpyrimidine
- 2-Amino-5-(4-chlorophenylethynyl)-4-(4-hydroxypiperidino)pyrimidine
- 4-(2-Hydroxyethylamino)-5-phenylethynylpyrimidine
- 10 2-Amino-4-(2-hydroxyethylamino)-5-phenylethynylpyrimidine
- 2-Amino-4-(4-hydroxyanilino)-5-phenylethynylpyrimidine
- 2-Amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-n-pentylphenylethynyl)  
pyrimidine
- 2-Acetamido-4-(4-trans-acetoxycyclohexylamino)-5-(4-chlorophenylethynyl)  
15 pyrimidine
- 2-Amino-5-(4-t-butylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyphenylethylamino)pyrimidine
- 2-Amino-4-(4-hydroxyanilino)-5-(4-methoxyphenylethynyl)pyrimidine
- 20 2-Amino-5-(4-propylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino)  
pyrimidine
- 2-Amino-4-(4-hydroxy-2-methylanilino)-5-(4-chlorophenylethynyl)pyrimidine
- 2-Amino- 5-(4-chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine
- 2-Amino-5-(4-chlorophenylethynyl)-4-(4-oxocyclohexyloxo)pyrimidine
- 25 2-amino-5-(4-chlorophenylethynyl)-4-[2-(2-hydroxyethoxy)ethoxy] pyrimidine
- 2-amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyphenoxy)pyrimidine
- 2-amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyphenylthio)pyrimidine, and
- 5-(4-chlorophenylethynyl)-2-formamido-4-(4-hydroxyphenylthio)pyrimidine
- and the pharmaceutically acceptable esters, amides, salts or solvates thereof.
- 30 Preferred compounds of the present invention are:

- 4-(4-Hydroxyanilino)-5-phenylethynylpyrimidine  
5-(4-Chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine  
2-Amino-4-[2-(2-hydroxyethoxy)ethylamino]-5-(4-methylphenylethynyl)pyrimidine  
5 2-Amino-4-(trans-hydroxycyclohexylamino)-5-(4-methylphenylethynyl)pyrimidine  
5-(4-Chlorophenylethynyl)-2-formamido-4-(4-trans-hydroxycyclohexylamino)pyrimidine  
2-Amino-5-(3,4-dichlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)  
10 pyrimidine  
2-Amino-5-(4-chlorophenylethynyl)-4-(4-oxocyclohexylamino)pyrimidine  
2-Amino-5-(2-chlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine  
2-Amino-5-(4-bromophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)  
15 pyrimidine  
2-Amino-5-(4-chlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine-O-dimethylphosphate ester  
2-Amino-5-(4-chlorophenylethynyl)-4-(3,4-dimethoxyanilino)pyrimidine  
5-(4-Acetamidophenylethynyl)-2-amino-4-(4-trans-hydroxycyclohexylamino)  
20 pyrimidine  
and the pharmaceutically acceptable esters, amides, salts or solvates thereof.

Particularly preferred compounds of the present invention are:

- 25 5-(4-Chlorophenylethynyl)-4-(trans-4-hydroxycyclohexylamino)pyrimidine  
2-Amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine  
2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-phenylethynylpyrimidine  
2-Amino-5-(4-chlorophenylethynyl)-4-(trans-4-hydroxycyclohexylamino)pyrimidine  
30 2-Amino-5-(4-chlorophenylethynyl)-4-(cis-4-hydroxycyclohexylamino)pyrimidine

2-Amino-4-[2-(2-hydroxyethoxy)ethylamino]-5-phenylethynylpyrimidine

2-Amino-5-(4-chlorophenylethynyl)-4-(2-hydroxyethylamino)pyrimidine

2-Amino-5-(4-ethylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine

5 and the pharmaceutically acceptable esters, amides, salts or solvates thereof.

In one aspect of the invention, compounds of the present invention are provided for use in medical therapy, particularly for the treatment of neurodegenerative or neurological disorders of the central or peripheral  
10 nervous systems.

Examples of nervous system disorders which may be treated in accordance with the invention include dementing disorders such as age-related senility, senile dementia or Age Related Mental Impairment (ARMI), cerebral ataxia,  
15 Parkinson's disease, Alzheimer's disease, peripheral neuropathy, cognitive disorders secondary to stroke or trauma and attention-deficit hyperactivity disorder. In addition, nerve injuries, for example, spinal cord injuries, that require neuroregeneration may also be treated in accordance with the invention.

20

In another aspect of the invention, compounds of the present invention are provided for use in the treatment of seizure disorders such as epilepsy.

In a further aspect of the invention, compounds of the present invention are  
25 provided for use in the treatment of diabetes.

In a further aspect of the present invention there is included:

a) A method for the treatment of neurodegenerative or neurological disorders  
30 of the central or peripheral nervous systems which comprises treating the subject, e.g., a mammal, such as a human, with a therapeutically effective

amount of a compound of the present invention;

b) A method for the treatment of seizure disorders which comprises treating the subject, e.g., a mammal such as a human, with a therapeutically effective  
5 amount of a compound of the present invention;

c) A method for the treatment of diabetes which comprises treating the subject, e.g., a mammal such as a human, with a therapeutically effective amount of a compound of the present invention; and  
10

d) The use of a compound of the present invention in the manufacture of a medicament for the treatment of any of the above mentioned disorders.

In addition, since the compounds of the present invention have been shown  
15 to enhance differentiation signals but not mitotic signals to cells in culture, the compounds can be used in clinical situations where enhancement of differentiation signals would be of benefit to the patient, as, for example, in the study of tumors derived from stem cells where the differentiation signals are overpowered by the mitotic signals.

20 Examples of pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts. However, salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compounds of the present invention. Preferred salts  
25 include those formed from hydrochloric, hydrobromic, sulfuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, oxaloacetic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, benzenesulfonic and isethionic acids.

30 Examples of pharmaceutically acceptable esters of the compounds of the present invention include straight chain or branched aliphatic esters such as

the formyl, acetyl, n-butyl, isobutyl and t-butyl esters, aromatic or substituted aromatic esters such as the benzoyl, naphthoyl and p-chlorobenzoyl esters, alkylaryl esters such as the phenylacetyl, naphthylacetyl and benzyl esters, and amino acid esters such as the L-valyl, L-isoleucyl and L-phenylalanyl  
5 esters. Many of these esters are hydrolysed to the compounds of Formula I upon administration to mammals and accordingly constitute prodrugs of the compounds of Formula I.

The compounds of the present invention and pharmaceutically acceptable  
10 esters, amides, salts or solvates thereof may be employed in combination with other therapeutic agents for the treatment of the above disorders. Examples of such further therapeutic agents include COGNEX, ARICEPT and other agents (e.g., acetylcholine esterase inhibitors, muscarinic or nicotinic receptor agonists, MAO inhibitors) that are effective for the treatment of  
15 neurodegenerative or neurological disorders of the central or peripheral nervous systems. The component compounds of such combination therapy may be administered simultaneously in either separate or combined formulations, or at different times, e.g., sequentially such that a combined effect is achieved.

20 While it is possible for compounds of the present invention to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation. The formulations of the present invention comprise a compound of Formula I, as above defined, or a pharmaceutically acceptable ester,  
25 amide, salt or solvate thereof, together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

30 The formulations include those suitable for oral, parenteral (including subcutaneous, transdermal, intradermal, intramuscular and intravenous),

rectal and topical (including dermal, buccal and sublingual) administration although the most suitable route may depend upon, for example, the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods  
5 well known in the art of pharmacy. All methods include the step of bringing into association a compound of Formula I or a pharmaceutically acceptable salt, ester amide or solvate thereof (active ingredient) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active  
10 ingredients with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each  
15 containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion, or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

20

Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions  
25 which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for Example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for Example, water-for-injection, immediately prior to use. Extemporaneous  
30 injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.



Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain  
5 the active compound 1) in an optionally buffered, aqueous solution or 2) dissolved and/or dispersed in an adhesive or 3) dispersed in a polymer. A suitable concentration of the active compound is about 1% to 35%, preferably about 3% to 15%. As one particular possibility, the active compound may be delivered from the patch by electrotransport or iontophoresis, as generally  
10 described in Pharmaceutical. Res., **3**(6), 318 (1986).

Preferred unit dosage formulations are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of the active ingredient.

15 It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question. For example, those suitable for oral administration may include flavoring  
20 agents.

For the above-mentioned conditions and disorders, the compounds of the Formula I are preferably administered orally or by injection (intraparenteral or subcutaneous). The precise amount of compound administered to a patient  
25 will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also the route of administration is likely to vary depending on the condition and its severity.

30 In chronic dosing for each of the above-mentioned indications, the compounds of Formula I may be administered orally by tablets or other forms

of presentation in discrete units which may contain from about 0.5 mg to 500 mg and generally from about 1 mg to 250 mg of compound. The typical oral dose range for adult humans is from about 1 to 1000 mg/day, and generally from about 5 to 250 mg/day. The compounds of Formula I may be  
5 administered by injection at a dose of from about 1 to 1000 mg/day, and generally from about 5 to 1000 mg/day. In clinical situations where acute dosing is appropriate, higher doses of from two to ten times the chronic dose may be utilized.

10 The present invention further includes processes for the preparation of compounds of Formula I and esters, amides, salts or solvates thereof by the methods hereinafter described, or in any manner known in the art for the preparation of compounds of analogous structure.

15 Esters and amides of the compounds of the present invention can be made by reaction with a carbonylating agent (e.g., ethyl formate, acetic anhydride, methoxyacetyl chloride, benzoyl chloride, methyl isocyanate, ethyl chloroformate, methanesulfonyl chloride) and a suitable base (e.g., 4-dimethylaminopyridine, pyridine, triethylamine, potassium carbonate) in a  
20 suitable organic solvent (e.g., tetrahydrofuran, acetone, methanol, pyridine, N,N-dimethylformamide) at a temperature of 0°C to 60°C, and preferably 20°C to 30°C.

Salts of the compounds of Formula I can be made from the free base form by  
25 reaction with the appropriate acid.

The following examples are directed to the preparation of representative compounds of the present invention and certain intermediates useful in their preparation. The examples are presented for purposes of illustration only and  
30 should not be construed as limiting the scope of the present invention.

## Example 1

## Preparation of 5-iodoisocytosine

5 Sodium hydroxide pellets (12.72 g) were dissolved in deionized water (318 mL) in a 1 liter round bottom flask and 2-amino-4-hydroxypyrimidine (35.0 g) was added with stirring. After the solids dissolved, iodine flakes (79.95 g) were added in one portion and the mixture was heated to 90-100°C for approximately 2.5 hours. The mixture was filtered while hot and the solid was  
10 washed liberally with water, rinsed with methanol, and dried under vacuum at 115°C to give 5-iodoisocytosine: 72.5 g.

## Example 2

## Preparation of 4-chloro-2-diisopropylaminomethyleneamino-5-iodopyrimidine

15 A solution of 4.5 mL of oxalyl chloride in 35 mL of dichloromethane was added dropwise over 25 minutes to an ice water bath-cooled solution of 7.0 mL of N,N-diisopropylformamide in 65 mL of dichloromethane with magnetic stirring. After a few minutes, 4.74 g of 2-amino-4-hydroxy-5-iodopyrimidine  
20 was added in one portion. The bath was removed and the solution was stirred at room temperature for 30 minutes, then refluxed for one and one half hours. The solution was cooled and poured into an equal amount of ice-cold saturated aqueous sodium bicarbonate with stirring. The two phases were partitioned and the organic layer washed with additional bicarbonate(2x),  
25 water(1x) and finally saturated aqueous brine. After drying over sodium sulfate and filtration, the solution was evaporated in vacuo to yield 10.13 g of a reddish oil. The oil was purified by column chromatography on silica gel, eluting with dichloromethane. Like fractions were pooled, evaporated and triturated with hexanes to give white free flowing crystals, 5.94 g, m.p. 97-  
30 100°C.

## Example 3

## Preparation of 4-chloro-5-(4-chlorophenylethynyl)pyrimidine

- 5 A mixture of 0.6 g of 1-chloro-4-ethynylbenzene, 1.44 g of 4-chloro-5-iodopyrimidine (J.Chem. Soc. Perkins Trans.I, 1977,621, Allen et al), 7.0 cc of triethylamine, 58 mg of copper iodide and 108 mg of dichlorobis(triphenylphosphine)palladium II was stirred at room temperature under nitrogen for 18 hours. The reaction mixture was evaporated in vacuo.
- 10 The resulting tan solid was partitioned between water and dichloromethane and the organic extracts washed twice with water, dried over sodium sulfate and evaporated to give a dark brown solid, 1.57 g. The solid was redissolved in dichloromethane and hexanes added to give 120 mg of a beige powder after filtration. The filtrate was purified by column chromatography on silica
- 15 gel using 1:1 ethyl acetate/dichloromethane as the eluant. The middle rf spot fractions (silica gel TLC in 1:1) were pooled and evaporated to give 0.8 g of a yellow solid, 4-chloro-5-(4-chlorophenylethynyl)-pyrimidine

## Example 4

- 20 Preparation of 5-(4-chlorophenylethynyl)-4-(trans-4-hydroxycyclohexylamino)pyrimidine

- A mixture of 0.46 g of 4-chloro-5-(4-chlorophenylethynyl)pyrimidine, 3.0 mL of dichloromethane, 3.0 mL of acetonitrile, 1.7 mL of triethylamine and 0.92 g
- 25 of trans-4-aminocyclohexanol hydrochloride was refluxed for 18 hours. The mixture was evaporated in vacuo and partitioned between dichloromethane and water. The organic phase was washed an additional time with water, dried over sodium sulfate, filtered and evaporated to give 0.54 g of a yellow foam. It was dissolved in dichloromethane and applied to a column of fine
- 30 mesh silica gel in the same solvent. The column was eluted with 1:1 ethyl acetate/dichloromethane, then the product was eluted with ethyl acetate to

yield, after evaporation, 0.53 g of a brittle foam. An aliquot was triturated with ether to give the desired product 5-(4-chlorophenylethynyl)- 4-(trans-4-hydroxycyclohexylamino)pyrimidine as a 0.2 M hydrate, m.p. 151-155°C.

5    Example 5

Preparation of 4-chloro-5-phenylethynylpyrimidine

A mixture of 2.1 g of 4-chloro-5-iodopyrimidine, 10 mL of triethylamine, 1.2 mL phenylacetylene, 80 mg copper iodide and 160 mg of  
10    dichlorobis(triphenylphosphine) was stirred at room temperature for 18 hours. The mixture was diluted with dichloromethane and evaporated in vacuo. The residue was redissolved in a few mL of dichloromethane, 10 mL of triethylamine added and the mixture heated at reflux for one hour. The heterogeneous mixture was evaporated in vacuo and the residue obtained  
15    was partitioned between water and dichloromethane. A gelatinous precipitate which formed on shaking the two layers was filtered off, enabling separation of the two layers. The organic extracts were dried over sodium sulfate, filtrated and evaporated in vacuo to yield 2.5 g of a dark brown syrup. The syrup was purified by column chromatography on silica gel, twice, eluting with  
20    hexanes, 1:1 hexanes/dichloromethane, dichloromethane and finally ethyl acetate. Like fractions from dichloromethane elution were pooled, obtaining 350 mg of the product, 5-phenylethynyl-4-chloropyrimidine as an oil which solidified to white rosettes.

25    Example 6

Preparation of 4-(trans-4-hydroxycyclohexylamino)-5-phenylethynylpyrimidine

A mixture of 0.2 g of 5-phenylethynyl-4-chloropyrimidine, 10 mL of acetonitrile, 0.42 g of trans aminocyclohexanol and 0.4 mL of triethylamine  
30    was refluxed overnight with magnetic stirring. The mixture was cooled and filtered and the filtrate evaporated in vacuo. The residue was purified by

column chromatography on silica gel, eluting successively with dichloromethane, 1:1 dichloromethane and finally ethyl acetate. The product, 4-(trans-4-hydroxycyclohexylamino)-5-phenylethynylpyrimidine, 200 mg, was obtained on evaporation of the latter eluate.

#### Example 7

Preparation of 4-chloro-2-diisopropylaminomethyleneamino-5-phenylethynylpyrimidine

A mixture of 2.46 g 4-chloro-2-diisopropylaminomethyleneamino-5-iodopyrimidine, 7.5 mL triethylamine, 0.064 g copper iodide, 0.12 g dichlorobis(triphenyl)phosphine palladium II and 0.9 mL phenylacetylene was stirred under nitrogen at room temperature for two days. The dark brown mixture was evaporated in vacuo at a bath temperature of 30-35°C. The residue was partitioned between dichloromethane and water. The organic phase was washed thrice with water, dried over sodium sulfate, filtered and evaporated to yield 3.37 g of a dark brown oil. The residue was dissolved in hexanes and purified by column chromatography on silica gel, eluting successively with hexanes, 1:1 dichloromethane /hexanes and dichloromethane. The product was obtained from the latter eluant to yield after evaporation, 1.69 (74%) g of 4-chloro-2-diisopropylaminomethyleneamino-5-phenylethynylpyrimidine.

#### Example 8

Preparation of 2-diisopropylaminomethyleneamino-4-(trans-4-hydroxycyclohexylamino)-5-phenylethynylpyrimidine

A mixture of 0.5 g of 4-chloro-2-diisopropylaminomethyleneamino-5-phenylethynylpyrimidine, 15 mL of acetonitrile, 0.67 g of trans 4-aminocyclohexanol hydrochloride and

1.8 mL of triethylamine was refluxed with magnetic stirring 18 hours. The mixture was chilled, filtered and the precipitate washed with acetonitrile. The filtrate was evaporated in vacuo and the resulting rust colored residue dissolved in dichloromethane. The solution was loaded on a column of fine mesh silica gel. The column was eluted with dichloromethane, then successively with 10%, 30%, 60% ethyl acetate in dichloromethane, ethyl acetate and finally 10% methanol in dichloromethane. Recovered starting material, 4-chloro-2-diisopropylaminomethyleneamino- 5-phenylethynylpyrimidine, 0.180 g was obtained on evaporation of the 10% ethyl acetate eluate. The product, 2-diisopropylaminomethyleneamino-4-trans-4-hydroxycyclohexylamino-5-phenylethynylpyrimidine, 0.32 g, was obtained from evaporation of the 60% and subsequent eluates.

#### Example 9

Preparation of 2-amino-4-(trans-4-hydroxycyclohexylamino)-5-phenylethynylpyrimidine

A solution of 0.24 g of 2-diisopropylaminomethyleneamino-4-(trans-4-hydroxycyclohexylamino- 5-phenylethynyl-pyrimidine in 5.0 mL each of ethanol and 4% aqueous sodium hydroxide was refluxed for 18 hours. The solution was evaporated in vacuo and the residue extracted with dichloromethane. The extracts were washed with water and dried over sodium sulfate. The filtered solution was loaded on a column of fine mesh silica gel in the same solvent. After washing the column with dichloromethane and acetonitrile, the product was eluted with 5% and 10% methanol in dichloromethane, to obtain on evaporation 0.1 g of a brittle foam. The product was converted to the hydrochloride by addition of ethanolic HCl to a solution of the base in 1:1 ether-ethanol to a pH of 2.0. The resulting solution was evaporated in vacuo and triturated with acetone and dried to yield 0.063 g of a yellow solid, one spot by TLC (10% methanol in dichloromethane).

## Example 10

Preparation of 4-chloro-5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneamino- pyrimidine

- 5 A mixture of 0.722g 4-chloro-2-diisopropylaminomethyleneamino-5-iodopyrimidine, 3.5 mL triethylamine, 0.025 g copper iodide, 0.037 g dichlorobis(triphenyl)phosphine palladium II and 0.289 g 1-chloro-4-ethynylbenzene was stirred under nitrogen at room temperature for 18 hours. The dark brown mixture was evaporated in vacuo
- 10 at a bath temperature of 30-35<sup>0</sup> C. The beige residue was partitioned between dichloromethane and water. The organic phase was washed twice with water, dried over sodium sulfate, filtered and evaporated to yield 1.0 g of a caramel colored film. The residue was dissolved in 1:1 dichloromethane /hexanes and purified by column chromatography on silica gel, eluting successively with 1:1
- 15 dichloromethane /hexanes, dichloromethane and ethyl acetate. The product was recovered from the latter two eluates by evaporation to yield 0.7 g of 4-chloro-5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneaminopyrimidine.

## 20 Example 11

Preparation of 5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneamino-4- (trans-4-hydroxycyclohexylamino)pyrimidine

- A mixture of 0.46 g of 4-chloro-5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneamino- pyrimidine, 15 mL of acetonitrile, 2 mL of
- 25 triethylamine and 0.56 g of trans- 4-aminocyclohexanol hydrochloride was refluxed 18 hours with magnetic stirring. The mixture was chilled, filtered and the precipitate washed with acetonitrile. The filtrate was evaporated in vacuo and the resulting rust colored residue dissolved in dichloromethane. The
- 30 solution was loaded on a column of fine mesh silica gel. The column was eluted with dichloromethane, yielding 0.19 g of starting material, 5-(4-



chlorophenylethynyl)-2-diisopropylaminomethyleneamino-4-chloropyrimidine, with ethyl acetate and finally 10% methanol in dichloromethane to give 0.53 g of 5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneamino- 4-(trans-4-hydroxycyclohexylamino)- pyrimidine. The <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>) was  
5 consistent with the structure.

#### Example 12

Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-(trans-4-hydroxycyclohexylamino)pyrimidine

10

A mixture of 1.25 g of 4-chloro-5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneamino- pyrimidine, 33 mL of ethanol, 2.02 g of trans-4-aminohexanol hydrochloride and 1.9 mL of triethylamine was stirred at reflux for three days. The clear amber solution was evaporated in vacuo  
15 and the beige solid was partitioned between dichloromethane and water. A portion of the solid insoluble in either phase was filtered off. It weighed 0.24 g and was identical on TLC(silica gel in ethyl acetate) to the product obtained from the organic phase. The organic phase was dried over sodium sulfate, filtered and evaporated in vacuo to give 0.67 g. Purification of the latter by  
20 column chromatography on silica gel was effected by first eluting the column with dichloromethane and 50% ethyl acetate in dichloromethane. Elution with ethyl acetate and evaporation yielded 190 mg of the desired product, 2-amino-5-(4-chlorophenylethynyl)-4-(trans- 4-hydroxycyclohexylamino)pyrimidine. An analytical sample was obtained by  
25 recrystallization of the material filtered from the reaction from 2-propanol and water, 0.19 g . m.p. 215-218 °C,

## Example 13

Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-(2-hydroxyethylamino)pyrimidine

5

A mixture of 0.7 g of 4-chloro-5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneamino-pyrimidine, 20 mL ethanol and 0.6 mL ethanolamine was refluxed for 18 hours. The green solution was evaporated in vacuo and triturated with water. The insoluble yellow residue was  
10 recrystallized by dissolving in 35 mL hot methanol, concentrating to 10 mL and chilling. The pale yellow powdery precipitate was filtered and dried to yield 0.34 g of 2-amino-5-(4-chlorophenylethynyl)-4-(2-hydroxyethylamino)pyrimidine, m.p. 197-200°C.

## 15 Example 14

Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-[2-(2-hydroxyethoxy)ethylamino]pyrimidine

A mixture of 0.3 g of 4-chloro-5-(4-chlorophenyl)-ethynyl-2-  
20 diisopropylaminomethyleneamino- pyrimidine, 6.0 mL ethanol and 0.26 g of 2-(2-aminoethoxy)ethanol was refluxed for 18 hours. The reaction mixture was evaporated in vacuo, the yellow solid dissolved in dichloromethane and loaded on a column of silica gel in the same solvent. The column was eluted successively with dichloromethane, 5% and 10% methanol/dichloromethane .  
25 The product 0.15 g was obtained from evaporation of the 10% eluate as a pale yellow solid. Recrystallization from boiling methanol gave 0.17 g of 2-amino-5-(4-chlorophenylethynyl)-4-[2-(2-hydroxyethoxy)ethylamino]pyrimidine. m.p. 176-180°C

## Example 15

Preparation of 4-(4-acetylpiperazino)-2-amino-5-(4-chlorophenylethynyl)pyrimidine

5 A mixture of 0.8 g of 4-chloro-5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneamino-pyrimidine, 35 mL acetonitrile and 0.71 g 1-acetyl piperazine was refluxed for one and one half hours. A green solution initially forms and the color changes  
10 to amber on continued heating. The solution was evaporated in vacuo and partitioned between dichloromethane and water. The organic phase was washed twice with water, dried over sodium sulfate, filtered and evaporated. The orange-brown brittle foam obtained was purified by column chromatography on silica gel, eluting initially with dichloromethane and then  
15 with 15% methanol/dichloromethane to give the intermediate derivative, 4-(4-acetyl piperazino)-5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneaminopyrimidine. Heating 0.6 g of the intermediate with 40 mL methanolic ammonia in a bomb at 120° C for 18 hours gave on evaporation in vacuo, a cocoa-colored residue which was  
20 purified by column chromatography on silica gel. The desired product 4-(4-acetylpiperazino)-2-amino-5-(4-chlorophenylethynyl)pyrimidine was obtained by elution with 5% methanol/dichloromethane, evaporation and trituration with methanol yielding 0.27 g, m.p. 165° C.

## 25 Example 16

Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine

A mixture of 0.932 mM of 5-(4-Chlorophenylethynyl)-2-diisopropylaminomethyleneamino- 4-chloropyrimidine and 0.102 g of 4-aminophenol in 5 mL ethanol was stirred at room temperature for four days.  
30

The brown solution was evaporated in vacuo (bath temperature 30<sup>0</sup> C) to obtain a brownish-burgundy solid. The residue was stirred in dichloromethane and filtered to yield 0.4 g of 5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneamino-4-(4-hydroxyanilino) pyrimidine. The <sup>1</sup>H NMR spectrum (CDCL<sub>3</sub>) was consistent with this structure. A mixture of 0.37 g of this product was heated in a bomb with 32 mL of methanolic ammonia at a temperature of 100<sup>0</sup>C for five hours. The cooled bomb contents were evaporated in vacuo and triturated with ice cold water and dried to yield a mixture of the desired 2-amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine with 2,4-diamino-5-(4-chlorophenylethynyl)pyrimidine.

#### Example 17

Preparation of 5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneamino-4-morpholinopyrimidine

A mixture of 0.46 g of 4-chloro-2-diisopropylaminomethyleneamino-5-(4-chlorophenylethynyl)-pyrimidine, 40 mL of acetonitrile and 0.41 g of morpholine was stirred at room temperature for 18 hours. The mixture was evaporated in vacuo and the residue partitioned between water and dichloromethane. The organic layer was washed once more with water, dried over sodium sulfate and filtered. The filtrate was loaded on a column of silica gel equilibrated in the same solvent. After elution of an unknown impurity, the product eluted as a yellow band. Additional material was obtained by a final elution with 1:1 dichloromethane and ethyl acetate. Like fractions of the two eluants were pooled and evaporated to give 0.63 g of a yellow oil, 5-(4-Chlorophenylethynyl)-2-diisopropylaminomethyleneamino-4-morpholinopyrimidine.

## Example 18

## Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-morpholinopyrimidine

- 5 A solution of 0.63 g of 5-(4-chlorophenylethynyl)-2-diisopropylaminomethyleneamino-4-morpholinopyrimidine and 35 mL of freshly prepared saturated methanolic ammonia was heated in a bomb at 60°C for 18 hours. The bomb was cooled, opened and the yellow solution was cooled. A precipitate formed which was filtered to give 0.2 g of a yellow
- 10 solid. Thin layer chromatography (silica gel in 20% ethyl acetate in dichloromethane) showed the filtrate displayed two spots, the upper one corresponding to the starting material and the lower to the precipitate. The latter was homogeneous and its <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) was consistent with the desired product, 2-amino-5-(4-chlorophenylethynyl)-4-morpholinopyrimidine.
- 15 The filtrate was evaporated and recharged with methanolic ammonia in a bomb at 80°C for 18 hours. After a similar workup, an additional crop, 0.16 g of 2-amino-5-(4-chlorophenylethynyl)-4-morpholinopyrimidine was obtained. Analytical samples as lustrous champagne colored flakes were obtained by recrystallization from boiling MeOH, m.p. 193-194°C.

20

## Example 19

## Preparation of 2-amino-4-[2-(2-hydroxyethoxy)ethylamino]-5-phenylethynyl pyrimidine

- 25 A mixture of 1.5 g of 4-chloro-2-diisopropylaminomethyleneamino-5-phenylethynylpyrimidine, 20mL of ethanol and 1.83 g of 2-(2-aminoethoxy)ethanol was refluxed for 18 hours. The tea colored solution was evaporated in vacuo and the residue partitioned between water and dichloromethane. The aqueous layer was washed twice more with
- 30 dichloromethane and the combined organic extracts washed with water. The

organic solution was dried over sodium sulfate, filtered and evaporated *in vacuo*. The yellow residue obtained was triturated with ether and filtered to give 0.49 g of a yellow solid, 2-amino-4-[2-(2-hydroxyethoxy)ethylamino]-5-phenylethynylpyrimidine. m.p. 128-129 °C.

5

#### Example 20

##### Preparation of 4-(4-hydroxyanilino)-5-phenylethynylpyrimidine hydrochloride

A mixture of 0.23 g of 4-chloro--5-(4-phenylethynyl)pyrimidine, 8 mL of  
10 ethanol and 0.12 g of 4-hydroxyaniline was stirred at room temperature for 18 hours. The heterogeneous mixture was filtered, washed with ether and dried to yield 0.189 g of a yellow powder 4-(4-hydroxyanilino)-5-phenylethynylpyrimidine hydrochloride, m.p. 223-225 °C, with decomposition.

#### 15 Example 21

##### Preparation of 5-(4-chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine hydrochloride

A mixture of 0.28 g of 4-chloro-5-(4-Chlorophenylethynyl)pyrimidine, 10 mL of  
20 ethanol and 0.14 g of 4-hydroxyaniline was stirred at room temperature for 18 hours. The black mixture was evaporated in *vacuo* and the residue was triturated with dichloromethane, ethylacetate and acetonitrile. The combined organic extracts were absorbed on silica gel and evaporated *in vacuo*. The powder was added to a column of silica gel equilibrated in dichloromethane  
25 and eluted with the same solvent. The column was eluted with ethyl acetate and then 10% methanol in dichloromethane. These eluates on evaporation produced 100 mg of the 5-(4-chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine hydrochloride as a muddy yellow powder.

## Example 22

Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-(4-oxocyclohexylamino)pyrimidine

5

Oxalyl chloride (1.52 g) and dichloromethane (50 mL) were combined under a nitrogen atmosphere and cooled to – 78 °C in a dry ice-acetone bath.

Dimethyl sulfoxide (1.88 g) was added dropwise via syringe through a rubber septum cap. After completion of the addition, solid 2-amino-5-(4-

10 chlorophenylethynyl)-4-(4-*trans*-hydroxycyclohexylamino)pyrimidine (3.43 g) was added in one portion and the mixture was stirred for 30 minutes.

Triethylamine (7 mL) was added in portions via syringe and after completion of the addition the cooling bath was removed and the mixture was allowed to warm to room temperature. The mixture was poured into water (40 mL) and

15 the organic phase was separated; it was washed with water (1 x 50 mL), brine (1 x 50 mL), dried over sodium sulfate, filtered and stripped *in vacuo* to a yellow foam. The product was purified by chromatography on silica gel (30 g) using a mixture of dichloromethane and ethyl acetate. Fractions corresponding to the desired product were pooled and stripped *in vacuo* to give 2-amino-5-(4-chlorophenylethynyl)-4-(4-oxocyclohexylamino)pyrimidine as  
20 a yellow powder: 2.32 g; m.p. 176-178C.

## Example 23

Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-(4-*cis*-  
25 hydroxycyclohexylamino)pyrimidine

2-Amino-5-(4-chlorophenylethynyl)-4-(4-oxocyclohexylamino)pyrimidine (1.02 g) was dissolved in sodium dried tetrahydrofuran (100 mL) under a nitrogen atmosphere and the mixture was cooled to - 78°C in a dry ice-acetone bath.

30 Lithium tri-*sec*-butylborohydride (6 mL, 1.0 mM in THF) was added via syringe through a rubber septum cap and the mixture was stirred for 1.5 hours. The

reaction mixture was quenched by addition of saturated aqueous ammonium chloride solution (8 mL) at - 78°C and then warmed to approximately 10-15°C and decanted from the white solids which had formed. The solids were washed with dichloromethane and the combined filtrates were stripped *in vacuo* and redissolved in dichloromethane. The solution was washed with 2 M sodium hydroxide (1 x 50 mL), brine (1 x 50 mL), dried over sodium sulfate, filtered and stripped *in vacuo* to a foam. The *cis/trans* mixture of amino alcohols was purified by chromatography on silica gel (10 g) using methylenechloride/acetone as eluent. Fractions containing the *cis*-amino alcohol by tlc were pooled and stripped *in vacuo* and the residue was crystallized from 95% aqueous ethanol to give 2-amino-5-(4-chlorophenylethynyl)-4-(4-*cis*-hydroxycyclohexylamino)pyrimidine as light yellow plates; 458.4 mg; m.p. 186-187°C.

#### Example 24

##### Preparation of 4-ethyl-1-ethynylbenzene

A mixture of 5.6 mL of 1-ethyl-4-iodobenzene, 75 mL of triethylamine, 6 mL of trimethylsilylacetylene, 0.49 g of dichlorotriphenylphosphine palladium II and 0.314 g copper iodide was magnetically stirred at ambient temperature for 18 hrs. The thick dark brown mixture was filtered, washing the gray precipitate with hexanes. The filtrate and washings were evaporated in *vacuo* and the residue dissolved in hexanes. This solution was 96.7% pure by GC analysis. The solution was passed down a column of silica gel which had been equilibrated in the same solvent and the eluates evaporated in *vacuo* to yield 9.3 g of 4-ethyl-1-trimethylsilyl ethynylbenzene as a dark amber liquid.

The residue was dissolved in 50 mL of methanol and stirred with 0.55 g of potassium carbonate at room temperature for 2.5 hrs. The mixture was evaporated in *vacuo* with the bath temperature at 60 °C. The resulting dark



residue was partitioned between dichloromethane and water, the organic phase washed with 0.1N aqueous HCl and filtered off some sludge from the organic phase. The extracts were dried over sodium sulfate, filtered and flash evaporated to give a dark brown liquid. The liquid was stirred in hexanes, filtered and loaded on a column of silica gel in hexanes. Elution with this solvent gave a colorless solution, which on flash evaporation gave 3.44 g of 4-ethyl-1-ethynylbenzene as a pale yellow liquid, GC purity 99.4%.

#### Example 25

Preparation of 4-chloro-2-diisopropylaminomethyleneamino-5-(4-ethylphenylethynyl)pyrimidine

A mixture of 6.3 g of 4-chloro-2-diisopropylaminomethyleneamino-5-iodopyrimidine, 33 mL of triethylamine, 2.43 g of 4-ethyl-1-ethynylbenzene, 0.304 g of dichlorobis(triphenyl)phosphine palladium II and 0.21 g copper iodide was magnetically stirred at reflux temperature for 1.5 hrs. The mixture was filtered and the filtrate evaporated *in vacuo*. Both the precipitate and the evaporated filtrate were dissolved in dichloromethane and washed with water, dried over sodium sulfate, filtered and evaporated. The residues were dissolved in 1:1 dichloromethane-hexanes and separately purified by column chromatography. After initial elution with 1:1 dichloromethane-hexanes, the product was obtained by elution with dichloromethane and 50% ethyl acetate-dichloromethane. Evaporation of the eluates gave 4.04 g of 4-chloro-2-diisopropylaminomethyleneamino-5-(4-ethylphenylethynyl)pyrimidine as a thick amber syrup.

#### Example 26

Preparation of 2-amino-5-(4-ethylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino) pyrimidine hydrochloride

A mixture of 1.925 mM of 4-chloro-2-diisopropylaminomethyleneamino-5-(4-

ethylphenyl) ethynylpyrimidine and 0.89 g of trans 4-aminocyclohexanol in 5.0 mL of absolute ethanol was heated in a bomb at 120 ° C for 18 hours. After removal, the dark amber bomb solution was evaporated *in vacuo* and co- evaporated with acetone. The residue was washed with water and the  
5 water insoluble material flash evaporated with acetone. The residue was dissolved in 5% methanol in dichloromethane and applied to a column of silica gel in the same solvent. Evaporation of the 5% eluates provided 600 mg of a tan solid. which was dissolved in ethanol and acidified with EtOAc-HCl to a pH of 1.0. Addition of excess ether and chilling gave 0.21 g of 2-amino-5-(4-  
10 ethylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino) pyrimidine hydrochloride. m.p. 240-255°C.

#### Example 27

Preparation of 5-(4-bromophenylethynyl)-4-chloro-2-  
15 diisopropylaminomethyleneaminopyrimidine

A mixture of 0.5 g of 1-bromo-4-ethynylbenzene, 5.0 mL of triethylamine, 0.031 mg of copper iodide, 0.94 g of 4-chloro-2-diisopropylaminomethylene-amino-5-iodopyrimidine and 0.046 g of dichlorobis(triphenyl)phosphine  
20 palladium II was magnetically stirred at room temperature for 18 hrs. The mixture was diluted with acetonitrile , filtered and the filtrate evaporated in vacuo. The evaporated filtrate was dissolved in dichloromethane and loaded on a column of silica gel equilibrated in the same solvent. Cuts were monitored by thin layer chromatography. After initial cuts of brown colored  
25 eluates, the product subsequently eluted as yellow fractions. Like cuts were pooled and evaporated to give 0.84g of 5-(4-bromophenylethynyl)-4-chloro-2-diisopropylaminomethyleneaminopyrimidine as a thick amber syrup.

## Example 28

Preparation of 2-amino-5-(4-bromophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine hydrochloride

- 5 A mixture of 1.3 g of 5-(4-bromophenylethynyl)-4-chloro-2-diisopropylaminomethyleneamino-pyrimidine and 1.48 g of trans 4-amino-cyclohexanol in 16 mL of absolute ethanol was refluxed for 18 hrs. The solvent was distilled off at atmospheric pressure and the residue cooled and triturated with water. The water insoluble residue was dissolved in methanol and azeotropically dried by co-evaporation (flash) with acetone. The olive green residue was dissolved in methanol, preabsorbed on silica gel, evaporated and applied to a column of silica gel equilibrated in ethyl acetate. The product was eluted with ethyl acetate and evaporated to give a pale green foamy residue, 0.74 g of 2-amino-5-(4-bromophenylethynyl)-4-(4-trans-hydroxy cyclohexylamino)pyrimidine. The solid was recrystallized from a minimum amount of boiling ethanol and chilled. A small amount of precipitate was obtained (80 mg) of an unknown substance, which was different by TLC from the filtrate. The pH of the filtrate was adjusted to 2.0 with HCl in EtOAC and the solution evaporated *in vacuo* to give a yellow solid. The solid was triturated with ether and filtered to give 0.69 g of a buttermilk powder. The solid was triturated with water to remove any amine hydrochloride, then dried. The material, 0.23 g analyzed as the anhydrous salt 2-amino-5-(4-bromophenylethynyl)-4-(4-trans-hydroxycyclohexylamino) pyrimidine hydrochloride, m.p 240 °C with decomposition .

25

## Example 29

Preparation of 1-acetamido-4-ethynylbenzene

- A mixture of 1.0 g of 4-ethynylaniline and 2.4 mL of acetic anhydride in 5.0 mL of dichloromethane was stirred at room temperature for 18 hours. The solution was evaporated in vacuo at 40 °C . The resulting semi solid mixture

was suspended in hexanes and filtered. The hexanes filtrate was washed twice with water and dried over sodium sulfate. After filtering it was combined with the hexanes insoluble residue, dissolved in dichloromethane and purified by column chromatography in the same solvent to yield 0.96 g of 1-  
5 acetamido-4-ethynylbenzene.

#### Example 30

Preparation of 5-(4-acetamidophenylethynyl)-4-chloro-2-diisopropylaminomethyleneamino-pyrimidine

10

The compound was prepared following the general method of Example 27 with the addition of acetonitrile as a reaction solvent.

#### Example 31

15 Preparation of 5-(4-acetamidophenylethynyl)-2-amino-4-(4-trans-hydroxycyclohexylamino)-pyrimidine hydrochloride

The compound was prepared following the general method of Example 28. m.p. 238-245°C with decomposition.

20

#### Example 32

Preparation of 4-chloro-2-dimethylaminomethyleneamino-5-iodopyrimidine

N,N-dimethylformamide (54.1 g) and dry acetonitrile (500 mL) were combined under nitrogen in a 4 liter round bottom flask. Oxalyl chloride (93.9 g) was  
25 added dropwise over a 1 hour period to form the intermediate Vilsmeier reagent and the HCl was vented through an aqueous sodium hydroxide scrubber. Solid 5-iodoisocytosine (77g, 0.32 moles) was added in one portion and the mixture was heated at 60°C for approximately 3 hours. The mixture  
30 was cooled to about 25°C and the solids were filtered and washed with

acetonitrile. The filter cake was slurried with deionized water (500 mL) and sodium bicarbonate (29 g) was added to maintain pH 8. The solids were filtered, washed with water, and dried in vacuo at 50°C to give 4-chloro-2-dimethylaminomethyleneamino-5-iodopyrimidine: 88 g m.p. 99-100°C.

5

### Example 33

Preparation of 4-chloro-5-(4-chlorophenylethynyl)-2-dimethylaminomethyleneaminopyrimidine

- 10 A 1-liter, 3-neck-round-bottom flask was equipped with an air stirrer, reflux condenser, and a nitrogen inlet. The 4-chloro-2-(dimethylaminomethyleneamino)-5-iodopyrimidine (65.2 g), ethanol (84 mL), and triethylamine (336 mL) were charged and heated to reflux. Copper (I) iodide (105 mg) and dichlorobis(triphenyl)phosphine palladium II (386 mg)
- 15 were added. Neat 1-chloro-4-ethynylbenzene (30.1 g) was added and the mixture was refluxed approximately 2.5 hours. The mixture was cooled to ambient temperature, stirred for 1.5 hours and filtered. The filter cake was slurried in water:ethanol (4:1 v/v, 120 mL), filtered and dried *in vacuo* at 50°C to give 4-chloro-5-(4-chlorophenylethynyl)-2-
- 20 dimethylaminomethyleneaminopyrimidine as a yellow solid: 55.7 g m.p. 195-197°C.

### Example 34

Preparation of 4-chloro-5-(4-chlorophenylethynyl)-2-formamidopyrimidine

25

4-Chloro-5-(4-chlorophenylethynyl)-2-dimethylaminomethyleneaminopyrimidine (65.1 g), isopropanol (585 mL), and water (36 mL) were combined and warmed to 60°C. Methane sulfonic acid (23.1 g) was added and heating at 60°C was continued for 1.5-2.0 hours or

30 until HPLC analysis confirmed the absence of the starting material. The

mixture was cooled to ambient temperature and held for 1.5 hours. The solids were removed by filtration and washed with isopropanol (100 mL). The filter cake was slurried in water (500 mL), basified with 1N NaOH to pH 11, filtered, and the solids were rinsed with water. Vacuum drying at 50°C  
5 provided predominantly 4-chloro-5-(4-chlorophenylethynyl)-2-formamidopyrimidine: 51.6 g.

#### Example 35

Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-(4-trans-  
10 hydroxycyclohexylamino)pyrimidine

4-Chloro-5-(4-chlorophenylethynyl)-2-formamidopyrimidine (42.9 g), n-propanol (344 mL), and trans-4-aminocyclohexanol (51.7 g) were combined and heated to reflux. HPLC analysis confirmed that the reaction was complete  
15 in approximately 4 hours. The mixture was cooled and held at ambient temperature for 1.5 hours and the yellow solids were filtered and washed with ethanol (200 mL). The filter cake was slurried in water (250 mL), adjusted to pH 10 with 1N NaOH, and filtered. The filter cake was washed with water (200 mL) and dried in vacuo at 50°C to give 2-amino-5-(4-  
20 chlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine: 41.2 g m.p. 216-218°C.

#### Example 36

Preparation of 2-amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-  
25 nitrophenylethynyl)pyrimidine hydrochloride

The compound was prepared in two steps by the methods of example 17 (at reflux temperature, 3.5 hrs) and example 12 (using four equivalents of the free base of 4-trans hydroxycyclohexylamine, in refluxing n-propanol, 18  
30 hrs).m.p.255°C.

## Example 37

Preparation of 2-amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-propylphenylethynyl)pyrimidine hydrochloride

5

A mixture of 5.0 g of 4-bromopropylbenzene, 15 mL of dichloromethane, 0.64 g of copper iodide, 0.32 g of dichlorobis(triphenyl)phosphine palladium II, 3.7 mL of trimethylsilylacetylene and 12.3 mL of triethylamine was refluxed for 18 hrs. The mixture was evaporated in vacuo (bath temperature 48 °C). The  
10 dark residue was dissolved in hexanes and passed through a pad of silica gel, washing the column well with additional solvent. The eluates were evaporated, redissolved in hexanes and purified on a column of silica gel in the same solvent. The fractions were monitored by thin layer chromatography. The initial cut contained two spots, the next a trace of the  
15 upper spot and the subsequent ones only the lower spot. The latter two were evaporated separately and analyzed by GC showing. 66 and 86% purity respectively. These eluates were combined and evaporated in vacuo to give 3.0 g of 1-propyl-4-trimethylsilylbenzene. The liquid was combined with 10 mL of methanol and 0.16 g of potassium carbonate and stirred at room  
20 temperature for three hours. The mixture was partitioned between hexanes and 0.5 N aqueous HCl. The organic layer was washed twice with water and dried over sodium sulfate. Evaporation of the filtered extracts gave 1.96 g of a honey colored liquid,  
1-ethyny-4-n-propylbenzene, 75.8% purity by GC.

25

The subsequent steps in the preparation of the subject compound followed the general procedure of Example 33, giving 90 mg of 2-amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-propylphenylethynyl)pyrimidine hydrochloride, m.p. 198-200°C.

## Example 38

Preparation of 2-amino-4-(4-hydroxyanilino)-5-(4-methoxyphenylethynyl)pyrimidine hydrochloride

5

The compound was prepared following the general procedures of examples 8 and 16. The diisopropylmethine protecting group on the 2-amino substituent was removed by refluxing in ethanol with three equivalents of 6 N aqueous HCl for one hour to give 2-amino-4-(4-hydroxyanilino)-5-(4-methoxyphenylethynyl)pyrimidine hydrochloride. m.p. 220-230 ° C with decomposition.

## Example 39

Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine-O-dimethylphosphate

15

2-Amino-5-(4-chlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine

(3.43 g) was dissolved in dry tetrahydrofuran (150 mL) under nitrogen. The solution was cooled to -78°C in a dry ice/acetone bath and a solution of lithium diisopropylamide (5.2 mL, 2.0 mM in THF) was added in portions. After an additional one hour, dimethylchlorophosphate (1.52 g) was added, the cooling bath was removed, and the mixture was allowed to warm to ambient temperature and stir overnight. The mixture was stripped *in vacuo* and the residue was partitioned between dichloromethane:ethyl acetate (200 mL, 3:1 v/v) and washed with saturated aqueous sodium bicarbonate (50 mL). The organic phase was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and stripped *in vacuo*. The residue was purified by chromatography on aluminum oxide (grade I, neutral) using ethyl acetate as eluent. Homogeneous fractions by tlc were pooled and stripped *in vacuo* to give 1.68 g. 2-amino-5-(4-

20

25

30



chlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine-O-dimethyl phosphate as a yellow foam.

#### Example 40

- 5 Preparation of 5-(4-chlorophenylethynyl)-2-formamido-4-(4-oxocyclohexyloxy)pyrimidine ethylene ketal

1,4-Dioxaspiro[4,5]decane-8-ol (1.74 g) was dissolved in dry dimethylformamide (40 mL) under a nitrogen atmosphere and sodium hydride (440 mg, 60% oil dispersion) was added. 4-Chloro-5-(4-chlorophenylethynyl)-2-dimethylaminomethyleneaminopyrimidine (3.19 g) was then added in one portion after hydrogen evolution had subsided. The mixture was stirred for 2 hours, stripped in vacuo, and the oily residue was redissolved in ethyl acetate (250 mL). The solution was washed with water (3 x 200 mL), brine (1x 200 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and stripped in vacuo. The residue was dissolved in dichloromethane and purified by chromatography on silica gel (50 g) with a dichloromethane/ethyl acetate gradient. Fractions containing the product by tlc were pooled and stripped *in vacuo*. The residue was recrystallized from hot ethyl acetate to give 1.89 g. of 5-(4-chlorophenylethynyl)-2-formamido-4-(4-oxocyclohexyloxy)pyrimidine ethylene ketal.

#### Example 41

- 25 Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-(4-oxocyclohexyloxy)pyrimidine

5-(4-Chlorophenylethynyl)-2-formamido-4-(4-oxocyclohexyloxy)pyrimidine ethylene ketal (1.66 g) was dissolved in tetrahydrofuran (75 mL) and 6M aqueous hydrochloric acid (10 mL). The mixture was stirred at ambient temperature for 3 hours and stripped *in vacuo*. The residue was partitioned between water and ethyl acetate (150 mL) and basified with 2M aqueous

sodium hydroxide. The organic phase was washed with water (1 x 100 mL), brine (1 x 100 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and stripped in vacuo. The residue was recrystallized from hot 2-propanol to give 2-amino-5-(4-chlorophenylethynyl)-4-(4-oxocyclohexyloxy)pyrimidine: 0.88 g; m.p. 168-172°C.

#### Example 42

Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-[2-(2-hydroxyethoxy)ethoxy] pyrimidine

11g of Diethylene glycol and 0.78g of a 60% suspension of sodium hydride in mineral oil were stirred in 200 ml of tetrahydrofuran (dried over sieves) for 15 minutes then 1.3 g of 4-chloro-5-(4-chlorophenylethynyl)-2-formamido-pyrimidine was added and the mixture was stirred at 25 °C in a dry atmosphere (drying tube) for 40 hours. The reaction mixture was then evaporated under reduced pressure at 55 °C. The resulting syrup was stirred with 250 ml of ethyl acetate, 125 ml of saturated aqueous sodium bicarbonate and 125 ml of water for 15 minutes. The organic phase was washed with 250 ml of water and then 100 ml of brine. After drying over sodium sulfate, the filtered solution was combined with 16 g of Silica gel 60 (230-400 mesh) and evaporated under reduced pressure. The solids were applied to column of silica gel 60 (2.5 x 9.5 cm). The final height of the column was 16 cm. After eluting the column with increasing concentrations of ethyl acetate in dichloromethane, the product-rich fractions were combined and the solvent evaporated under reduced pressure. The product was recrystallized twice from ethyl acetate to give 0.75g of the desired product, m.p. 142-143°C.

#### Example 43

Preparation of 2-amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyphenoxy) pyrimidine

The compound was prepared following the general method of Example 42 substituting hydroxyquinone for diethylene glycol as the starting material. m.p. 250-251°C.

5 Example 44

Preparation of

(I) 2-amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyphenylthio)pyrimidine, and  
(II) 5-(4-chlorophenylethynyl)-2-formamido-4-(4-hydroxyphenylthio)pyrimidine

10 0.45g of 4-mercaptophenol and 0.86g of a 60% suspension of sodium hydride in mineral oil were stirred in 200 ml of tetrahydrofuran (dried over sieves) for 45 minutes then 2.17g of 4-chloro-5-(4-chlorophenylethynyl)-2-formamidopyrimidine was added and the mixture was stirred at 25 °C under nitrogen for 5.5 hours. The reaction mixture was then filtered and the filtrate  
15 evaporated under reduced pressure at 50 °C. The resulting residue was stirred with 300 ml of ethyl acetate and 250 ml of water for 45 minutes. The organic phase was washed with 250 ml of water and then 100 ml of brine. After drying over stirred sodium sulfate for 6.5 hrs. the cloudy suspension was filtered and the filtrate was combined with 11 g of silica gel 60 (230-400  
20 mesh) and evaporated under reduced pressure at 50 °C. The dried solids were applied to a column of silica gel 60 (2.5 x 6 cm). The final height of the column was 12 cm. After eluting the column with increasing concentrations of ethyl acetate in methylene chloride, the fractions were allowed to stand at 25 °C for 48 hours. Precipitates formed in two groups of fractions. Each was  
25 collected separately by filtration and washed with methylene chloride. The white solid from the earlier fractions was dried in vacuo at 105 °C, m.p. 266-267°C° (0.13g). The elemental analysis was consistent with the structure 5-(4-chlorophenylethynyl)-2-formamido-4-(4-hydroxyphenylthio)pyrimidine. The light yellow solid obtained from the later fractions was dried in vacuo at 105  
30 °C, m.p. 261-262 C° (0.18g). The elemental analysis was consistent with the

structure 2-amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyphenylthio)pyrimidine.

Compounds (I) and (II) of Example 44 are subject to *ex vivo* or *in vivo* oxidation at the 4-position to produce the corresponding sulfoxide and/or sulfone derivatives, and such derivatives compounds are included within the scope of the present invention.

#### Assay for Activity

The compounds of the present invention were assayed for neurotrophic activity as follows:

##### A. Screen for NGF-like Activity:

Cultured PC12 cells (rat adrenal pheochromocytoma from ATCC) have receptors for NGF. Responses include promotion of neurite outgrowth and elevation of choline acetyltransferase (ChAT) (L.A. Greene and A.S. Tischler, Cell Neurobiol., 3, 373 (1982)).

The following assay is modified from that described in HL White and PW Scates, Neurochem. Res., 16, 63 (1991). PC12 cells were cultured at 37° C in RPMI supplemented with HEPES buffer, pH7.5 (to 10 mM), fetal bovine serum, horse serum, glutamine, penicillin, streptomycin and non-essential amino acids. Cultures were split 1:3 every 3 to 4 days. Exponentially dividing cells were plated into fresh medium on collagen-coated 12-well plastic dishes (10<sup>5</sup> cells/well). After allowing one day for cell attachment, the medium was replaced with low serum medium, with or without test compounds with each condition in triplicate. The medium may contain up to 0.2 % ethanol, which was used as a solvent for most compounds tested. Cells were examined for morphological changes using an Olympus IMT-2 inverted research

microscope. After 3 days incubation with test compounds, medium was removed and replaced with 0.2 ml of lysis and ChAT assay mixture. The plates were incubated at 37° C for 2 hours and then placed into a freezer at -20° C.

5

Compounds are judged NGF-like in this primary screen if they (1) increase the activity of ChAT, (2) enhance NGF-stimulated neurite outgrowth or (3) potentiate or appear additive with the action of NGF itself.

#### 10 B. Choline Acetyltransferase (ChAT) Assays:

The assay mixture contained 100 mM phosphate, pH7.4, 0.1% NP-40, 150 mM NaCl, 1.5 mM choline, 10 mM EDTA, 0.1 mM eserine, 0.1 mM acetyl-coenzyme A and about 0.5 uCi (40-70 Ci/mol) [<sup>14</sup>C]acetyl-coenzyme A in  
15 each ml of mixture. Thawed and lysed cell reaction mixtures were diluted to 1 ml with water and transferred to 7 ml scintillation vials containing 5 ml of extraction/scintillation fluid solution (50 mg triphenyl borate, 50 mg PPO, 20 mg POPOP per 100 ml of 20% acetonitrile/80% toluene) and vortexed for 10 seconds. After all  
20 diluted well contents were transferred and mixed, all the vials were vortexed again for 30 seconds, rotated for about 2 hours, and then vortexed once more. The vials were centrifuged at 3000 rpm (rmax. =16 cm) for 15 minutes and then counted in a Beckman LS6500 scintillation counter. Background counts from reaction mixtures with extracts from non-stimulated cells (no NGF  
25 and no test compound) were subtracted from reaction product counts before comparisons of ChAT activities were made.

The following data were obtained for representative compounds of the present invention which (1) increased the activity of choline acetyltransferase  
30 ChAT), (2) enhanced NGF-stimulated neurite outgrowth and/or (3) potentiated


or appeared additive with the action of NGF itself. The concentration at which the test compound doubled the ChAT activity over the activity with NGF alone (no test compound) was recorded as the  $EC_{2x}$  value. Among the more active compounds of the present invention are the following:

5

	<u>Compound of</u>	<u><math>EC_{2x}</math> (uM)</u>
	Example 4	0.2
	Example 9	0.1
	Example 12	0.2
10	Example 13	0.3
	Example 14	0.5
	Example 23	0.3
	Example 26	0.2

## CLAIMS

1. A compound of Formula I:



Formula I

wherein

Z is O, NH or S, and m is 0 or 1;

$R_1$  is  $(C2-6alkyl)_a (C3-10cycloalkyl, C2-9heterocycloalkyl, C5-10aryl, or C4-9heteroaryl)_b (C1-6alkyl)_c$ , wherein a, b and c are independently 0 or 1, provided that at least one of a, b and c is 1 and if b is 0, then c is also 0, and wherein the heterogroups include an N, O or S atom and the C and N atoms of  $R_1$  may optionally be substituted with one or more substituents selected from the group consisting of:

OH;

halogen;

thio;

oxo;

thioxo;

carboxy;

carboxamide;

C1-7alkylcarbonyl;

C1-7alkylcarbonyloxy

C1-7alkylthiocarbonyl;

C1-8alkyloxy;  
hydroxyC2-8alkyloxy;  
di-C1-8alkylphosphate ester  
C1-8alkylthio;  
5 hydroxyC2-8alkylthio;  
C1-8alkylsulfinyl;  
C1-8alkylsulfonyl;  
C1-5alkyloxyC1-5alkyl;  
C1-5alkylthioC1-5alkyl;  
10 C1-5alkylsulfinylC1-5alkyl; and  
C1-5alkylsulfonylC1-5alkyl;

$R_2$  is selected from the group consisting of H,  $NH_2$  and  
 $NH-CO-R_3$ , where  $R_3$  is H or C1-12 alkyl;

15

X is C6-10aryl optionally substituted with one or more  
substituents (y) selected from the group consisting of:

OH;  
 $NO_2$   
20  $NH_2$   
 $NH-CO-R_4$  where  $R_4$  is H, C1-12alkyl, aryl or (C1-6alkyl)aryl  
halogen;  
C1-6alkyl;  
hydroxyC1-6alkyl;  
25 oxoC2-7alkyl;  
C2-7alkenyl;  
C2-7alkynyl;  
C1-6alkoxy;  
 $CF_3$ ;  
30  $CF_3C1-6alkyl$ ;



OCF<sub>3</sub>; and

CF<sub>3</sub>C1-6alkoxy;

and pharmaceutically acceptable esters, amides, salts or solvates thereof.

5 2. A compound of Claim 1, wherein m is 1 and X is phenyl.

3. A compound of Claim 1, wherein m is 1, X is phenyl and R<sub>1</sub> is C2-6alkyl, C3-10cycloalkyl, C5-10aryl, or C5-10arylC2-6alkyl.

10 4. A compound of Claim 1, wherein m is 1, X is phenyl and R<sub>1</sub> is ethyl, cyclohexyl, phenyl or phenylethyl.

5. A compound of Claim 1, wherein m is 0, X is phenyl and R<sub>1</sub> is piperidino or piperazino.

15

6. A compound of Claim 1 selected from:

2-Amino-5-(4-chlorophenylethynyl)-4-(4-acetylpiperazino)pyrimidine,

4-(trans-4-Hydroxycyclohexylamino)-5-phenylethynylpyrimidine,

4-[2-(2-Hydroxyethoxy)ethylamino]-5-phenylethynylpyrimidine,

20 5-(4-Chlorophenylethynyl)-4-[2-(2-hydroxyethoxy)ethylamino]pyrimidine,

2-Amino-5-(4-chlorophenylethynyl)-4-[2-(2-hydroxyethoxy)ethylamino]pyrimidine,

4-(4-(2-Hydroxyethyl)piperazino)-5-phenylethynylpyrimidine,

2-Amino-4-(4-(2-hydroxyethyl)piperazino)-5-phenylethynylpyrimidine,

25 2-Amino-5-(4-chlorophenylethynyl)-4-(4-(2-hydroxyethyl)piperazino)pyrimidine,

4-(4-Hydroxypiperidino)-5-phenylethynylpyrimidine,

5-(4-Chlorophenylethynyl)-4-(4-hydroxypiperidino)pyrimidine,

2-Amino-4-(4-hydroxypiperidino)-5-phenylethynylpyrimidine,

30 2-Amino-5-(4-chlorophenylethynyl)-4-(4-hydroxypiperidino)pyrimidine,

- 4-(2-Hydroxyethylamino)-5-phenylethynylpyrimidine,  
2-Amino-4-(2-hydroxyethylamino)-5-phenylethynylpyrimidine,  
2-Amino-4-(4-hydroxyanilino)-5-phenylethynylpyrimidine,  
2-Amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-n-pentylphenylethynyl)  
5 pyrimidine,  
2-Acetamido-4-(4-trans-acetoxycyclohexylamino)-5-(4-chlorophenylethynyl)  
pyrimidine,  
2-Amino-5-(4-t-butylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino)  
pyrimidine,  
10 2-Amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyphenylethylamino)pyrimidine,  
2-Amino-4-(4-hydroxyanilino)-5-(4-methoxyphenylethynyl)pyrimidine,  
2-Amino-5-(4-propylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino)  
pyrimidine,  
2-Amino-4-(4-hydroxy-2-methylanilino)-5-(4-chlorophenylethynyl)pyrimidine,  
15 2-Amino- 5-(4-chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine,  
2-Amino-5-(4-chlorophenylethynyl)-4-(4-oxocyclohexyloxy)pyrimidine,  
2-amino-5-(4-chlorophenylethynyl)-4-[2-(2-hydroxyethoxy)ethoxy] pyrimidine,  
2-amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyphenoxy)pyrimidine,  
2-amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyphenylthio)pyrimidine,  
20 5-(4-chlorophenylethynyl)-2-formamido-4-(4-hydroxyphenylthio)pyrimidine,  
4-(4-Hydroxyanilino)-5-phenylethynylpyrimidine,  
5-(4-Chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine,  
2-Amino-4-[2-(2-hydroxyethoxy)ethylamino]-5-(4-  
methylphenylethynyl)pyrimidine,  
25 2-Amino-4-(trans-hydroxycyclohexylamino)-5-(4-  
methylphenylethynyl)pyrimidine,  
5-(4-Chlorophenylethynyl)-2-formamido-4-(4-trans-hydroxycyclohexylamino)  
pyrimidine,  
2-Amino-5-(3,4-dichlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)  
30 pyrimidine,  
2-Amino-5-(4-chlorophenylethynyl)-4-(4-oxocyclohexylamino)pyrimidine,

2-Amino-5-(2-chlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)  
pyrimidine,

2-Amino-5-(4-bromophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)  
pyrimidine,

5 2-Amino-5-(4-chlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)  
pyrimidine-O-dimethylphosphate ester,

2-Amino-5-(4-chlorophenylethynyl)-4-(3,4-dimethoxyanilino)pyrimidine, and

5-(4-Acetamidophenylethynyl)-2-amino-4-(4-trans-hydroxycyclohexylamino)  
pyrimidine.

10

7. A compound of Claim 1 selected from:

5-(4-Chlorophenylethynyl)-4-(trans-4-hydroxycyclohexylamino)pyrimidine,

2-Amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine,

2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-phenylethynylpyrimidine,

15 2-Amino-5-(4-chlorophenylethynyl)-4-(trans-4-hydroxycyclohexylamino)  
pyrimidine,


2-Amino-5-(4-chlorophenylethynyl)-4-(cis-4-  
hydroxycyclohexylamino)pyrimidine,

2-Amino-4-[2-(2-hydroxyethoxy)ethylamino]-5-phenylethynylpyrimidine,

20 2-Amino-5-(4-chlorophenylethynyl)-4-(2-hydroxyethylamino)pyrimidine, and

2-Amino-5-(4-ethylphenylethynyl)-4-(4-trans-  
hydroxycyclohexylamino)pyrimidine.

8. A compound of Claim 1 according to Formula IA:




Formula IA

wherein p is 0, 1 or 2, and each y (which may be the same or different),  $R_1$  and  $R_2$  are as defined in Claim 1, and pharmaceutically acceptable esters, amides, salts and solvates thereof.

9. A compound of Claim 8, wherein  $R_1$  is C2-6alkyl, C3-10cycloalkyl, C5-10aryl, or C5-10arylC2-6alkyl.

10. A compound of Claim 8, wherein  $R_1$  is hydroxycyclohexyl, hydroxyphenyl, hydroxyphenylethyl, hydroxyethyl or hydroxyethoxyethyl

11. A compound of Claim 1 according to Formula IB



Formula IB


wherein p is 0,1 or 2, and each y (which may be the same or different),  
R<sub>1</sub> and R<sub>2</sub> are as defined in Claim 1, and pharmaceutically acceptable esters,  
amides, salts and solvates thereof.

5 12. A compound of Claim 11, wherein R<sub>1</sub> is C2-6alkyl, C3-10cycloalkyl, C5-10aryl, or C5-10arylC2-6alkyl.

13. A compound of Claim 11, wherein R<sub>1</sub> is hydroxycyclohexyl,  
hydroxyphenyl, hydroxyphenylethyl, hydroxyethyl or hydroxyethoxyethyl.

10

14. A compound of Claim 1 according to Formula IC



Formula IC

15

wherein p is 0,1 or 2, and each y (which may be the same or different),  
R<sub>1</sub> and R<sub>2</sub> are as defined in Claim 1, and pharmaceutically acceptable esters,  
amides, salts and solvates thereof.

20 15. A compound of Claim 14, wherein R<sub>1</sub> is C2-6alkyl, C3-10cycloalkyl, C5-10aryl, or C5-10arylC2-6alkyl.

16. A compound of Claim 14, wherein R<sub>1</sub> is hydroxycyclohexyl,  
hydroxyphenyl, or hydroxyethoxyethyl.

25

17. A pharmaceutical composition, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier therefor.
18. A pharmaceutical composition, comprising a compound of Claim 6 or 7  
5 and a pharmaceutically acceptable carrier therefor.
19. A method of treating a mammal having a neurodegenerative or neurological disorder of the central or peripheral nervous system, which comprises administering to said mammal a therapeutically effective amount of  
10 a compound of Claim 1.
20. A method of treating a mammal having a neurodegenerative or neurological disorder of the central or peripheral nervous system, which comprises administering to said mammal a therapeutically effective amount of  
15 a compound of Claim 6 or 7.
21. A method according to Claim 19 or 20, wherein the disorder is Alzheimer's disease.
22. A method according to Claim 19 or 20, wherein the disorder is peripheral  
20 neuropathy.
23. A method according to Claim 19 or 20, wherein the disorder is senile dementia.  
25
24. A method according to claim 19 or 20, wherein the disorder is a seizure disorder.
25. A method of treating a mammal having diabetes, which comprises  
30 administering to said mammal a therapeutically effective amount of a compound of Claim 1.

26. A method of treating a mammal having diabetes, which comprises administering to said mammal a therapeutically effective amount of a compound of Claim 6 or 7.

5

# INTERNATIONAL SEARCH REPORT

In <span style="float: right;">al Application No</span> <b>PCT/US 01/23088</b>		
<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C07D239/34 C07D239/38 C07D239/42 C07D239/48 C07D239/46 A61K31/505 A61P25/00 A61P25/28 A61P3/10		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 19305 A (BEAUCHAMP LILIA M; KRENITSKY PHARMACEUTICALS INC (US); KELLEY JAME) 22 April 1999 (1999-04-22) cited in the application page 19, line 13 - line 32; claims ---	1-26
A	WO 99 02497 A (NOVARTIS ERFIND VERWALT GMBH; HECKENDORN ROLAND (CH); AUBERSON YVE) 21 January 1999 (1999-01-21) page 2, line 5 -page 4, line 9; claims 6,11; example 5 ---	1, 19, 21-24
A	EP 0 459 819 A (WELLCOME FOUND) 4 December 1991 (1991-12-04) cited in the application abstract ---	1, 19
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
° Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*Z* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">14 December 2001</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">27/12/2001</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Hass, C</div>



## INTERNATIONAL SEARCH REPORT

Int      nal Application No

PCT/US 01/23088

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 372 934 A (WELLCOME FOUND) 13 June 1990 (1990-06-13) claim 1	1,19
A	US 4 663 334 A (CARSON JOHN R) 5 May 1987 (1987-05-05) claims 1,16; example 4	1,17
A	US 5 719 303 A (FUKUDA YOSHIO ET AL) 17 February 1998 (1998-02-17) columns 79, 80, example no. 98 column 26, line 15 - line 53	1,17
A	EP 0 079 312 A (CIBA GEIGY AG) 18 May 1983 (1983-05-18) page 34, compounds no. 358 to 370	1
A	EP 0 508 469 A (DOWELANCO) 14 October 1992 (1992-10-14) page 11, line 15	1
A,P	WO 00 61562 A (BEAUCHAMP LILIA M; KRENITSKY PHARMACEUTICALS INC (US); KELLEY JAME) 19 October 2000 (2000-10-19) claims 1,7-17	1,8, 17-23

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No

PCT/US 01/23088

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9919305	A	22-04-1999	AU 9693998 A EP 1025091 A1 JP 2001519416 T WO 9919305 A2	03-05-1999 09-08-2000 23-10-2001 22-04-1999
WO 9902497	A	21-01-1999	AU 738973 B2 AU 8974398 A BR 9811685 A CN 1262676 T WO 9902497 A2 EP 0998459 A2 HU 0004225 A2 JP 2001509504 T NO 20000124 A PL 343865 A1 SK 232000 A3 TR 200000059 T2 ZA 9806137 A	04-10-2001 08-02-1999 19-09-2000 09-08-2000 21-01-1999 10-05-2000 28-05-2001 24-07-2001 02-03-2000 10-09-2001 12-06-2000 21-06-2000 22-01-1999
EP 0459819	A	04-12-1991	AT 141263 T AU 680252 B2 AU 6745594 A AU 652753 B2 AU 7809791 A CA 2043640 A1 CS 9101643 A3 DE 69121317 D1 DE 69121317 T2 DK 459819 T3 EP 0459819 A2 EP 0679645 A1 ES 2093078 T3 FI 912623 A FI 961410 A GR 3021237 T3 HU 58707 A2 HU 9500669 A3 IE 911861 A1 IL 98330 A IL 113599 A JP 6340634 A NO 180375 B NO 954109 A NZ 238360 A NZ 248501 A NZ 272001 A PL 166656 B1 PL 170373 B1 PT 97827 A ,B SK 278444 B6 RU 2091374 C1 ZA 9104165 A	15-08-1996 24-07-1997 15-09-1994 08-09-1994 05-12-1991 02-12-1991 19-02-1992 19-09-1996 02-01-1997 02-09-1996 04-12-1991 02-11-1995 16-12-1996 02-12-1991 28-03-1996 31-01-1997 30-03-1992 28-11-1995 04-12-1991 31-10-1996 30-09-1997 13-12-1994 30-12-1996 02-12-1991 24-03-1997 24-03-1997 24-03-1997 30-06-1995 31-12-1996 31-03-1992 07-05-1997 27-09-1997 01-03-1993
EP 0372934	A	13-06-1990	AP 164 A AT 144422 T AU 639216 B2 AU 4596489 A AU 4915493 A	12-01-1992 15-11-1996 22-07-1993 14-06-1990 13-01-1994

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/US 01/23088

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0372934 A		AU 5195296 A	18-07-1996
		AU 5195396 A	04-07-1996
		AU 690443 B2	23-04-1998
		AU 5195596 A	04-07-1996
		AU 5195696 A	04-07-1996
		CA 2004747 A1	07-06-1990
		CN 1052306 A	19-06-1991
		CN 1119099 A	27-03-1996
		CN 1115756 A , B	31-01-1996
		CN 1113487 A , B	20-12-1995
		CN 1117046 A	21-02-1996
		DD 292250 A5	25-07-1991
		DE 68927368 D1	28-11-1996
		DK 90399 A	24-06-1999
		DK 613289 A	08-06-1990
		EP 0372934 A2	13-06-1990
		EP 0727212 A2	21-08-1996
		EP 0727213 A2	21-08-1996
		EP 0727214 A2	21-08-1996
		EP 0713703 A2	29-05-1996
		EP 0715851 A2	12-06-1996
		ES 2095842 T3	01-03-1997
		FI 955939 A	11-12-1995
		FI 955940 A	11-12-1995
		FI 955941 A	11-12-1995
		GR 3022031 T3	31-03-1997
		HK 1004092 A1	13-11-1998
		HU 55764 A2	28-06-1991
		HU 9500740 A3	28-11-1995
		HU 9500754 A3	28-11-1995
		IE 80711 B1	16-12-1998
		IL 92558 A	31-01-1996
		IL 111627 A	10-06-1997
		IL 114335 A	06-12-2000
		JP 2202876 A	10-08-1990
		JP 2795498 B2	10-09-1998
		KR 145308 B1	15-07-1998
		LT 269 A , B	25-10-1994
		LV 10442 A , B	20-02-1995
		MC 2076 A	12-10-1990
		MX 9203422 A1	01-07-1992
US 4663334 A	05-05-1987	AU 597319 B2	31-05-1990
		AU 6642486 A	16-06-1988
		CA 1292739 A1	03-12-1991
		CN 86108922 A	05-08-1987
		DK 594686 A	12-06-1987
		EP 0226447 A2	24-06-1987
		FI 865028 A	12-06-1987
		HU 44013 A2	28-01-1988
		JP 62175460 A	01-08-1987
		NO 864987 A	12-06-1987
		NZ 218441 A	26-04-1989
		US 4728666 A	01-03-1988
		ZA 8609333 A	27-07-1988
US 5719303 A	17-02-1998	AU 6156494 A	26-09-1994
		EP 0688325 A1	27-12-1995

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/23088

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5719303	A		HU 72307 A2	29-04-1996
			WO 9420508 A1	15-09-1994
			JP 8508245 T	03-09-1996
			ZA 9401575 A	13-10-1994
EP 0079312	A	18-05-1983	CA 1223008 A1	16-06-1987
			EP 0079312 A2	18-05-1983
			JP 58090554 A	30-05-1983
			US 4508560 A	02-04-1985
			US 4626272 A	02-12-1986
EP 0508469	A	14-10-1992	US 5250532 A	05-10-1993
			AU 646942 B2	10-03-1994
			AU 1482592 A	15-10-1992
			BR 9201305 A	01-12-1992
			CA 2065746 A1	12-10-1992
			CN 1067426 A	30-12-1992
			DE 69228492 D1	08-04-1999
			DE 69228492 T2	24-06-1999
			EP 0508469 A1	14-10-1992
			HU 60729 A2	28-10-1992
			JP 6025225 A	01-02-1994
			MX 9201681 A1	01-10-1992
			US 5493024 A	20-02-1996
			US 5324837 A	28-06-1994
WO 0061562	A	19-10-2000	AU 4331400 A	14-11-2000
			WO 0061562 A1	19-10-2000